Breathe easily: Pulmatrix receives patents for its inhaled drug delivery tech and COPD drug

Clinical stage biopharmaceutical company, Pulmatrix, has received two important patents from the US Patent and Trademark Office for its inhaled drug delivery platform and its most advanced drug candidate for chronic obstructive pulmonary disease (COPD).

The patent covering the company’s drug delivery technology, iSPERSE, expands the number of excipients that can be used, increasing the platform’s versatility. “This patent doubles the choices that we have, extending the reach of our technology,” explained Robert W. Clarke, PhD, chief executive officer for Pulmatrix.

The second patent extends the protection of the company’s PUR0200 drug candidate for COPD, which now includes complete protection for the composition of the drug and certain dose ranges.

“The new PUR0200 patent will make it more difficult for potential competitors to develop similar products or to work around our product candidate,” explained Clarke. “The new claims also will make it possible for us to add in a second therapeutic to create a combination product.”.

Pulmatrix has revealed it is developing PUR0200 in both Europe and the US, following regulatory pathways that offer quicker approvals and lower costs.